Drug Profile
Research programme: molecular diagnostics - VECT-HORUS
Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator VECT-HORUS
- Class Diagnostic agents; Diagnostic conjugates; Peptides; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; CNS disorders
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in CNS-disorders(Diagnosis) in France
- 28 May 2019 No recent reports of development identified for research development in Cancer(Diagnosis) in France
- 01 Feb 2018 Advanced Accelerator Applications has been acquired by Novartis